Clinical and Genetic Delineation of Neurodegeneration with Brain Iron Accumulation

Overview

Journal J Med Genet

Specialty Genetics

Date 2008 Nov 5

PMID 18981035

Citations 135

Authors

A Gregory

B J Polster

S J Hayflick

Affiliations

Soon will be listed here.

Abstract

Neurodegeneration with brain iron accumulation (NBIA) describes a group of progressive neurodegenerative disorders characterised by high brain iron and the presence of axonal spheroids, usually limited to the central nervous system. Mutations in the PANK2 gene account for the majority of NBIA cases and cause an autosomal recessive inborn error of coenzyme A metabolism called pantothenate kinase associated neurodegeneration (PKAN). More recently, it was found that mutations in the PLA2G6 gene cause both infantile neuroaxonal dystrophy (INAD) and, more rarely, an atypical neuroaxonal dystrophy that overlaps clinically with other forms of NBIA. High brain iron is also present in a portion of these cases. Clinical assessment, neuroimaging, and molecular genetic testing all play a role in guiding the diagnostic evaluation and treatment of NBIA.

Citing Articles

The Neural Palette of Heme: Altered Heme Homeostasis Underlies Defective Neurotransmission, Increased Oxidative Stress, and Disease Pathogenesis.

Soladogun A, Zhang L Antioxidants (Basel). 2025; 13(12.

PMID: 39765770 PMC: 11672823. DOI: 10.3390/antiox13121441.

Neurodegeneration with brain iron accumulation 5: report of three cases.

Khalilian S, Fathi M, Ghahghaei-Nezamabadi A, Miryounesi M, Ghafouri-Fard S Neurogenetics. 2024; 26(1):14.

PMID: 39627470 DOI: 10.1007/s10048-024-00783-7.

A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study.

Pereira A, de Souza C, Alvarez-Cordoba M, Reche-Lopez D, Sanchez-Alcazar J Orphanet J Rare Dis. 2024; 19(1):442.

PMID: 39609877 PMC: 11606047. DOI: 10.1186/s13023-024-03453-x.

Iron Dyshomeostasis in Neurodegeneration with Brain Iron Accumulation (NBIA): Is It the Cause or the Effect?.

Agostini F, Sgalletta B, Bisaglia M Cells. 2024; 13(16).

PMID: 39195264 PMC: 11352641. DOI: 10.3390/cells13161376.

An overview of early-onset cerebellar ataxia: a practical guideline.

Hosseinpour S, Bemanalizadeh M, Mohammadi P, Ashrafi M, Heidari M Acta Neurol Belg. 2024; 124(6):1791-1804.

PMID: 38951452 DOI: 10.1007/s13760-024-02595-w.

References

Muthane U, Shetty R, Panda K, Yasha T, Jayakumar P, Taly A . Hallervordern Spatz disease and acanthocytes. Neurology. 1999; 53(8):32A. View

Paisan-Ruiz C, Bhatia K, Li A, Hernandez D, Davis M, Wood N . Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol. 2008; 65(1):19-23. PMC: 9016626. DOI: 10.1002/ana.21415. View

Newell K, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte E, Vonsattel J . Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol. 1999; 58(12):1263-8. DOI: 10.1097/00005072-199912000-00007. View

Galvin J, Giasson B, Hurtig H, Lee V, Trojanowski J . Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol. 2000; 157(2):361-8. PMC: 1850114. DOI: 10.1016/s0002-9440(10)64548-8. View

Saito Y, Kawai M, Inoue K, Sasaki R, Arai H, Nanba E . Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci. 2000; 177(1):48-59. DOI: 10.1016/s0022-510x(00)00337-3. View

Neumann M, Adler S, Schluter O, Kremmer E, Benecke R, Kretzschmar H . Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol. 2000; 100(5):568-74. DOI: 10.1007/s004010000224. View

Curtis A, Fey C, Morris C, Bindoff L, Ince P, Chinnery P . Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet. 2001; 28(4):350-4. DOI: 10.1038/ng571. View

Zhou B, Westaway S, Levinson B, Johnson M, Gitschier J, Hayflick S . A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet. 2001; 28(4):345-9. DOI: 10.1038/ng572. View

Koeppen A, Dickson A . Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol. 2001; 25(2):148-55. DOI: 10.1016/s0887-8994(01)00269-7. View

10.

Hayflick S, Penzien J, Michl W, Sharif U, ROSMAN N, Wheeler P . Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol. 2001; 25(2):166-9. DOI: 10.1016/s0887-8994(01)00296-x. View

11.

Ching K, Westaway S, Gitschier J, Higgins J, Hayflick S . HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology. 2002; 58(11):1673-4. DOI: 10.1212/wnl.58.11.1673. View

12.

Hayflick S, Westaway S, Levinson B, Zhou B, Johnson M, Ching K . Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med. 2003; 348(1):33-40. DOI: 10.1056/NEJMoa020817. View

13.

Hortnagel K, Prokisch H, Meitinger T . An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. Hum Mol Genet. 2003; 12(3):321-7. DOI: 10.1093/hmg/ddg026. View

14.

Mubaidin A, Roberts E, Hampshire D, Dehyyat M, Shurbaji A, Mubaidien M . Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum. J Med Genet. 2003; 40(7):543-6. PMC: 1735513. DOI: 10.1136/jmg.40.7.543. View

15.

Johnson M, Kuo Y, Westaway S, Parker S, Ching K, Gitschier J . Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann N Y Acad Sci. 2004; 1012:282-98. DOI: 10.1196/annals.1306.023. View

16.

Perez R, Melero R, Balboa M, Balsinde J . Role of group VIA calcium-independent phospholipase A2 in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. J Biol Chem. 2004; 279(39):40385-91. DOI: 10.1074/jbc.M402562200. View

17.

Szanto J, Gallyas F . A study of iron metabolism in neuropsychiatric patients. Hallervorden-Spatz disease. Arch Neurol. 1966; 14(4):438-42. DOI: 10.1001/archneur.1966.00470100094012. View

18.

Jellinger K, SEITELBERGER F, ROSENKRANZ W . [Infantile neuroaxonal dystrophy. Early form with preferential cerebellar involvement]. Acta Neuropathol. 1968; 10(2):123-31. DOI: 10.1007/BF00691306. View

19.

RADERMECKER J, Martin J . [Infantile neuro-axonal dystrophy and Hallervorden-Spatz disease. Electro-clinical and anatomo-pathological and differential diagnostic aspects]. Bull Acad R Med Belg. 1972; 12(7):459-502. View

20.

Dooling E, Schoene W, Richardson Jr E . Hallervorden-Spatz syndrome. Arch Neurol. 1974; 30(1):70-83. DOI: 10.1001/archneur.1974.00490310072012. View